Regencell Historical Balance Sheet

RGC Stock

USD 4.82 0.02 0.41%

Trend analysis of Regencell Bioscience Holdings balance sheet accounts such as Total Stockholder Equity of 7.8 M, Property Plant And Equipment Net of 193.7 K, Current Deferred Revenue of 224.8 M or Accounts Payable of 200 M provides information on Regencell Bioscience's total assets, liabilities, and equity, which is the actual value of Regencell Bioscience to its prevalent stockholders. By breaking down trends over time using Regencell Bioscience balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regencell Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regencell Bioscience is a good buy for the upcoming year.

Regencell Bioscience Inventory

(166,910)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

About Regencell Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Regencell Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Regencell Bioscience Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Regencell Bioscience and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Regencell currently owns. An asset can also be divided into two categories, current and non-current.

Regencell Bioscience Balance Sheet Chart

At present, Regencell Bioscience's Current Deferred Revenue is projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 118 K, whereas Total Assets are forecasted to decline to about 7.2 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Regencell Bioscience assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regencell Bioscience books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Regencell Bioscience balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Regencell Bioscience Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Regencell Bioscience's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	463.7K	85.7K	77.2K	73.3K
Total Assets	12.6M	8.4M	7.6M	7.2M

Short Long Term Debt Total Total Assets

Regencell Bioscience balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Receivables	Common Stock
Total Assets		0.95	0.97	0.99	-0.52	0.98	-0.39	0.93	0.88	-0.65	0.95	1.0	0.8	0.94	-0.43	0.99	0.91	0.95	0.61	0.19	0.96	0.99	0.92	-0.11	0.96	0.99
Short Long Term Debt Total	0.95		0.85	0.98	-0.76	0.88	-0.14	1.0	0.78	-0.54	0.83	0.95	0.93	0.83	-0.3	0.94	0.99	0.99	0.5	0.05	1.0	0.92	0.75	0.08	0.98	0.93
Other Current Liab	0.97	0.85		0.91	-0.32	0.99	-0.59	0.82	0.83	-0.75	0.96	0.96	0.62	0.95	-0.57	0.97	0.79	0.85	0.63	0.16	0.86	0.96	0.96	-0.31	0.87	0.98
Total Current Liabilities	0.99	0.98	0.91		-0.64	0.94	-0.25	0.97	0.87	-0.56	0.91	0.99	0.88	0.91	-0.33	0.97	0.96	0.98	0.56	0.19	0.99	0.98	0.85	0.01	0.99	0.97
Total Stockholder Equity	-0.52	-0.76	-0.32	-0.64		-0.38	-0.43	-0.8	-0.34	0.09	-0.33	-0.53	-0.9	-0.33	-0.11	-0.5	-0.82	-0.75	-0.1	0.19	-0.75	-0.48	-0.15	-0.49	-0.68	-0.48
Property Plant And Equipment Net	0.98	0.88	0.99	0.94	-0.38		-0.55	0.86	0.84	-0.74	0.95	0.98	0.67	0.95	-0.55	0.99	0.83	0.88	0.66	0.17	0.89	0.96	0.96	-0.27	0.9	0.99
Current Deferred Revenue	-0.39	-0.14	-0.59	-0.25	-0.43	-0.55		-0.1	-0.25	0.66	-0.48	-0.39	0.22	-0.48	0.74	-0.45	-0.06	-0.14	-0.4	-0.07	-0.15	-0.37	-0.61	0.86	-0.16	-0.47
Net Debt	0.93	1.0	0.82	0.97	-0.8	0.86	-0.1		0.75	-0.51	0.8	0.93	0.94	0.79	-0.26	0.92	1.0	0.99	0.49	0.02	1.0	0.9	0.71	0.12	0.97	0.91
Retained Earnings	0.88	0.78	0.83	0.87	-0.34	0.84	-0.25	0.75		-0.47	0.9	0.87	0.7	0.9	-0.2	0.84	0.74	0.81	0.54	0.47	0.8	0.91	0.88	0.05	0.86	0.84
Accounts Payable	-0.65	-0.54	-0.75	-0.56	0.09	-0.74	0.66	-0.51	-0.47		-0.63	-0.66	-0.25	-0.63	0.77	-0.7	-0.47	-0.49	-0.64	0.27	-0.54	-0.6	-0.72	0.46	-0.5	-0.71
Cash	0.95	0.83	0.96	0.91	-0.33	0.95	-0.48	0.8	0.9	-0.63		0.94	0.65	1.0	-0.51	0.93	0.79	0.84	0.53	0.28	0.85	0.98	0.93	-0.21	0.86	0.94
Non Current Assets Total	1.0	0.95	0.96	0.99	-0.53	0.98	-0.39	0.93	0.87	-0.66	0.94		0.8	0.93	-0.43	1.0	0.92	0.95	0.62	0.17	0.96	0.98	0.91	-0.11	0.96	0.99
Non Currrent Assets Other	0.8	0.93	0.62	0.88	-0.9	0.67	0.22	0.94	0.7	-0.25	0.65	0.8		0.65	0.02	0.76	0.96	0.93	0.33	0.11	0.93	0.78	0.52	0.39	0.92	0.74
Cash And Short Term Investments	0.94	0.83	0.95	0.91	-0.33	0.95	-0.48	0.79	0.9	-0.63	1.0	0.93	0.65		-0.5	0.93	0.79	0.84	0.53	0.27	0.85	0.98	0.92	-0.2	0.86	0.93
Good Will	-0.43	-0.3	-0.57	-0.33	-0.11	-0.55	0.74	-0.26	-0.2	0.77	-0.51	-0.43	0.02	-0.5		-0.49	-0.24	-0.26	-0.34	0.12	-0.3	-0.43	-0.5	0.8	-0.24	-0.5
Common Stock Shares Outstanding	0.99	0.94	0.97	0.97	-0.5	0.99	-0.45	0.92	0.84	-0.7	0.93	1.0	0.76	0.93	-0.49		0.9	0.94	0.63	0.14	0.95	0.97	0.92	-0.18	0.94	1.0
Non Current Liabilities Total	0.91	0.99	0.79	0.96	-0.82	0.83	-0.06	1.0	0.74	-0.47	0.79	0.92	0.96	0.79	-0.24	0.9		0.99	0.45	0.04	0.99	0.89	0.68	0.15	0.97	0.89
Inventory	0.95	0.99	0.85	0.98	-0.75	0.88	-0.14	0.99	0.81	-0.49	0.84	0.95	0.93	0.84	-0.26	0.94	0.99		0.46	0.16	0.99	0.93	0.76	0.09	0.98	0.93
Other Current Assets	0.61	0.5	0.63	0.56	-0.1	0.66	-0.4	0.49	0.54	-0.64	0.53	0.62	0.33	0.53	-0.34	0.63	0.45	0.46		-0.08	0.51	0.56	0.7	-0.1	0.56	0.63
Other Stockholder Equity	0.19	0.05	0.16	0.19	0.19	0.17	-0.07	0.02	0.47	0.27	0.28	0.17	0.11	0.27	0.12	0.14	0.04	0.16	-0.08		0.08	0.26	0.29	-0.14	0.22	0.15
Total Liab	0.96	1.0	0.86	0.99	-0.75	0.89	-0.15	1.0	0.8	-0.54	0.85	0.96	0.93	0.85	-0.3	0.95	0.99	0.99	0.51	0.08		0.93	0.77	0.08	0.98	0.94
Total Current Assets	0.99	0.92	0.96	0.98	-0.48	0.96	-0.37	0.9	0.91	-0.6	0.98	0.98	0.78	0.98	-0.43	0.97	0.89	0.93	0.56	0.26	0.93		0.91	-0.1	0.95	0.97
Short Term Debt	0.92	0.75	0.96	0.85	-0.15	0.96	-0.61	0.71	0.88	-0.72	0.93	0.91	0.52	0.92	-0.5	0.92	0.68	0.76	0.7	0.29	0.77	0.91		-0.29	0.81	0.93
Intangible Assets	-0.11	0.08	-0.31	0.01	-0.49	-0.27	0.86	0.12	0.05	0.46	-0.21	-0.11	0.39	-0.2	0.8	-0.18	0.15	0.09	-0.1	-0.14	0.08	-0.1	-0.29		0.08	-0.2
Net Receivables	0.96	0.98	0.87	0.99	-0.68	0.9	-0.16	0.97	0.86	-0.5	0.86	0.96	0.92	0.86	-0.24	0.94	0.97	0.98	0.56	0.22	0.98	0.95	0.81	0.08		0.93
Common Stock	0.99	0.93	0.98	0.97	-0.48	0.99	-0.47	0.91	0.84	-0.71	0.94	0.99	0.74	0.93	-0.5	1.0	0.89	0.93	0.63	0.15	0.94	0.97	0.93	-0.2	0.93

Click cells to compare fundamentals

Regencell Bioscience Account Relationship Matchups

Regencell Bioscience balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	340.1K	18.0M	12.6M	8.4M	7.6M	7.2M
Short Long Term Debt Total	3.7M	771.3K	463.7K	85.7K	77.2K	73.3K
Other Current Liab	655.8K	166.8K	168.7K	133.8K	120.4K	114.4K
Total Current Liabilities	4.3M	577.8K	606.9K	193.6K	174.2K	165.5K
Total Stockholder Equity	(4.0M)	17.1M	12.0M	8.2M	7.4M	7.8M
Property Plant And Equipment Net	81.9K	1.5M	891.9K	226.5K	203.9K	193.7K
Net Debt	3.6M	(5.6M)	(1.1M)	(2.9M)	(2.6M)	(2.5M)
Retained Earnings	(4.0M)	(11.4M)	(17.3M)	(21.6M)	(19.5M)	(18.5M)
Cash	59.4K	6.4M	1.6M	3.0M	2.7M	2.5M
Non Current Assets Total	273.3K	1.6M	1.0M	324.2K	291.8K	277.2K
Non Currrent Assets Other	191.4K	114.3K	108.5K	97.7K	112.3K	118.0K
Cash And Short Term Investments	59.4K	16.4M	11.6M	8.0M	7.2M	6.8M
Liabilities And Stockholders Equity	340.1K	18.0M	12.6M	8.4M	7.6M	7.2M
Non Current Liabilities Total	3.7M	360.3K	25.4K	25.9K	29.8K	28.3K
Total Liab	4.3M	938.0K	632.3K	219.5K	197.6K	187.7K
Total Current Assets	66.8K	16.4M	11.6M	8.1M	7.3M	6.9M
Short Term Debt	3.7M	411.0K	438.3K	59.8K	53.8K	51.1K
Property Plant And Equipment Gross	117.8K	1.6M	1.4M	1.0M	909.6K	864.1K
Net Invested Capital	(315.7K)	17.1M	12.0M	8.2M	9.5M	6.9M
Net Working Capital	(4.3M)	15.9M	11.0M	7.9M	9.1M	4.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:

How To Invest In Regencell

Details

Is Regencell Stock a good investment?

Details

What is Regencell Bioscience's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.33)

Return On Assets

(0.28)

Return On Equity

(0.43)

The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regencell Historical Balance Sheet

Regencell Bioscience Inventory

(166,910)

About Regencell Balance Sheet Analysis

Regencell Bioscience Balance Sheet Chart

Total Assets

Total Current Liabilities

Regencell Bioscience balance sheet Correlations

Regencell Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regencell Bioscience balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Net Debt
Total Liab	+ 1.0	Net Debt
Cash And Short Term Investments	+ 1.0	Cash

Non Currrent Assets Other	- 0.9	Total Stockholder Equity
Non Current Liabilities Total	- 0.82	Total Stockholder Equity
Net Debt	- 0.8	Total Stockholder Equity
Total Stockholder Equity	- 0.76	Short Long Term Debt Total
Total Liab	- 0.75	Total Stockholder Equity
Inventory	- 0.75	Total Stockholder Equity